Advanced Oncotherapy #AVO – Peter Gyllenhammar AB shareholding

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Advanced Oncotherapy plc 1b. Please indicate if the issuer is […]

Advanced Oncotherapy (AVO) – Financing facility provided by significant shareholders

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a consortium formed by AB Segulah and other investors has made available a £3.9m loan to the Company.  The loan will have a two year maturity and a 12% per annum rolled up interest rate.  The Segulah group includes AB Segulah, a […]